Bristol-Myers Squibb (BMY) shares surged Monday after AbbVie (ABBV) announced that its Phase 2 clinical trials for a potential schizophrenia treatment, emraclidine, failed to meet their primary endpoint. This news potentially benefits Bristol-Myers Squibb, which acquired Karuna Therapeutics, the company behind the first new schizophrenia drug approved in decades, last year.
AbbVie’s stock took a significant hit after two Phase 2 trials investigating emraclidine, a potential schizophrenia treatment, failed to meet their primary endpoint. Despite this setback, analysts remain positive on AbbVie’s overall pipeline, pointing to the promising Cerevel acquisition and other treatments in development. This news could also impact the schizophrenia drug market, with analysts questioning the effectiveness of selective muscarinic targeting and highlighting the potential advantages of Bristol Myers Squibb’s Cobenfy.
AbbVie Inc’s (ABBV) stock took a significant hit on Monday after disappointing results from its Phase 2 trials for emraclidine, a potential treatment for schizophrenia. The drug failed to meet its primary endpoint, leading to a 10.6% drop in AbbVie’s share price. The news comes as a setback for the company, which acquired emraclidine through its acquisition of Cerevel Therapeutics. Meanwhile, Bristol-Myers Squibb (BMY) saw its stock soar 13% after receiving FDA approval for its new schizophrenia medication, Cobenfy.
Bristol Myers Squibb exceeded third-quarter revenue expectations, driven by strong performance in its Growth Portfolio and Eliquis. However, analysts are focused on the company’s pipeline, particularly the recent approval of Cobenfy, for long-term growth potential. While revenue from Cobenfy is not expected until the second half of 2025, the potential for Alzheimer’s psychosis treatment could boost sentiment. Despite the positive earnings, BMY stock is down Friday.
The Schizophrenia Clinical Trial Pipeline is experiencing a surge in activity, driven by the pursuit of innovative treatments for this complex mental disorder. DelveInsight’s report, ‘Schizophrenia Pipeline Insight 2024,’ provides a comprehensive overview of the global pipeline, highlighting 60+ drugs in various stages of development by 55+ companies. Key players like Sumitomo Pharma, Boehringer Ingelheim, and Reviva Pharmaceuticals are at the forefront of this progress, developing new medications that promise to address both positive and negative symptoms, as well as cognitive impairments. The report explores the latest breakthroughs, emerging therapies, and the potential impact these advancements will have on the treatment landscape.
The FDA has approved Bristol Myers Squibb’s Cobenfy, an oral medication for schizophrenia in adults. Analysts predict significant potential for the drug, particularly in treating Alzheimer’s related psychosis, with projected peak sales exceeding $6 billion. However, despite its first-mover advantage, Cobenfy faces competition from AbbVie’s emraclidine, while potential side effects are also noted.
Karuna Therapeutics’ experimental drug, KarXT, is poised to receive FDA approval this month, potentially revolutionizing schizophrenia treatment. This innovative drug could offer relief for millions of Americans battling the debilitating disorder, marking the first significant breakthrough in over 70 years. However, concerns remain about accessibility due to high potential costs and systemic issues in the U.S. healthcare system.
Neurocrine Biosciences’ experimental drug, NBI-1117568, demonstrated positive results in a Phase 2 clinical trial for schizophrenia, showing a significant reduction in symptoms compared to placebo. The drug’s potential as a safer alternative to atypical antipsychotics has sparked optimism among analysts, leading to an upgrade in the company’s stock.
Neurocrine Biosciences’ experimental schizophrenia drug, NBI-1117568, demonstrated a statistically significant improvement in symptoms in a Phase 2 clinical trial, but the effect size was lower than some competing treatments. The company’s stock price dropped significantly following the news.
Scientists have discovered that a specific type of genetic material found in the human genome, known as Human Endogenous Retroviruses (HERVs), may be associated with higher susceptibility to neuropsychiatric disorders such as schizophrenia, bipolar disorder, and depression. By analyzing genetic data and postmortem brain tissue samples, researchers have identified five novel HERVs that are strongly linked to these conditions. The study suggests that these HERVs could potentially enhance the chances of developing psychiatric disorders, although further research is needed to determine the specific level of risk.
